Skip to content
Screener

Travere Therapeutics, Inc. TVTX Q4 2025 Annual earnings

Reported February 19, 2026 · After market close

Revenue$129.7MMiss by $14.9M
EPS$0.03In line
Revenue estimate$144.6M
EPS estimate$0.03

Next report

Oct 29, 2026 (in a month)
Revenue estimate$195.7M
EPS estimate$0.05

Financials

Q4 2025

Income statement

See full
Revenue$129.7M+73.4%
Gross profit$127.1M+76.0%
Operating income-$32.4M+46.6%

Balance sheet

See full
Cash & equivalents$93.0M+58.9%
Total debt$17.0M-81.4%
Total equity$114.8M+94.4%
Total assets$605.2M+1.9%

Cash flow

See full
Operating cash flow$60.7M+270%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.42B+125%
Enterprise value$3.34B+116%
P/S7×+0.5×

Profitability

See full
Gross margin97.9%+1.2pp
Operating margin-12.8%-6.1pp

Returns & leverage

See full
Debt / equity0.1×-1.4×
Current ratio2.7×+0.7×

Segments

By segment

See full
Reportable Segment$129.7M+73.4%

FAQ

When did Travere Therapeutics, Inc. report Q4 2025 earnings?
Travere Therapeutics, Inc. (TVTX) reported Q4 2025 earnings on February 19, 2026 after market close.
What were Travere Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Travere Therapeutics, Inc. reported revenue of $129.7M and eps of $0.03 for Q4 2025.
Did Travere Therapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $144.6M by $14.9M. EPS beat the consensus estimate of $0.03 by $0.00.
How did Travere Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 73.4% from $74.8M a year earlier.
Where can I find Travere Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001438533-26-000013) and the 10-K periodic report (0001438533-26-000014) directly on SEC EDGAR. The filing index links above go to sec.gov.